Cembra Money Bank AG (0QPJ)
London Exchange · UK · prices in CHF · close of 21 Oct 2026
Key indicators
| Last close | CHF 87.65 |
|---|---|
| 52-week range | 84.58 – 101.67 |
| Return, 1 month / 3 months | +0.2% / −0.8% |
| Return, 1 year / 3 years | +1.8% / +63.5% |
| Trend | Below its 200-day average |
| RSI (14) | 53 |
| Volatility (1 year) | 18.4% |
| Worst drawdown (1 year) | -15.4% |
| Average daily value traded | 2.40M CHF |
| Dividend yield | 5.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Cembra Money Bank is a Swiss consumer finance bank based in Zurich. It offers personal loans, credit cards, vehicle leasing and financing, and savings and deposit accounts to private customers across Switzerland. The bank also provides financing for retailers and dealers who offer credit to their customers, and it serves small businesses with selected lending products. Its services focus on consumer credit and savings for households in its home market.
On this site Cembra Money Bank AG appears as a stock on the London Exchange (UK), code 0QPJ, with prices in Swiss francs (CHF). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cembra Money Bank AG (0QPJ) trades on the London Exchange in UK. It last closed at CHF 87.65 on 21 October 2026.
Its price-based Market X-Ray is 58 out of 100 (a fair price profile), ranking 1,502 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 1.8% and over the last three months it fell 0.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 41 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -5.0% | ||
| From 52-week high | -12.4% | ||
| Momentum | 42 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -0.8% | ||
| 6-month return | -8.5% | ||
| 12-month return, skipping the last month | 1.6% | ||
| Stability (higher is calmer) | 87 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 18.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -15.4% | ||
| Liquidity | 61 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.40M CHF | ||
| Zero-volume days | 0.0% | ||
| Income | 65 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.2% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +0.6% |
|---|---|
| 1 month | +0.2% |
| 3 months | −0.8% |
| 6 months | −8.5% |
| 1 year | +1.8% |
| 3 years | +63.5% |
| 5 years | – |
Signals
| 50-day / 200-day average | 87.37 / 92.28 |
|---|---|
| Golden / death cross (60 days) | Death, 53 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.06 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 28 Apr 2026 | CHF 4.6000 |
| 28 Apr 2025 | CHF 4.2500 |
| 26 Apr 2024 | CHF 4.0000 |
| 25 Apr 2023 | CHF 3.9500 |
| 25 Apr 2022 | CHF 3.8500 |
| 26 Apr 2021 | CHF 3.7500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.